Subscribe To
Merck blockbuster shows promise in bladder cancer
Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster cancer drug Keytruda in people with cer...
October 5, 2023, 8:43 am
Koru medical systems to present two abstracts at the immunoglobulin national society 2023 national conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focus...
October 5, 2023, 7:05 am
Alx oncology announces proposed public offering
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), ...
October 4, 2023, 8:10 pm
Moderna reports positive results for combination flu and covid vaccine
Moderna Inc. announced positive interim results from a Phase 1/2 trial of its combination vaccine against COVID-19 and flu on Wednesday, and said it w...
October 4, 2023, 8:09 am
Pharvaris to present at the ciic fall 2023 conference
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...
October 4, 2023, 7:34 am
Beyond cancer™ selected to present proffered posters discussing data from the uno therapy program at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that i...
October 4, 2023, 7:30 am
Io biotech announces three poster presentations at the society for immunotherapy of cancer’s (sitc) 38th annual meeting
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
October 3, 2023, 8:30 pm
immunovant announces closing of upsized common stock financing and full exercise of underwriters’ option to purchase additional shares
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) — immunovant, Inc. (Nasdaq: IMVT), a clinical-stage ...
October 2, 2023, 8:52 pm
Cidara therapeutics reports inducement grant under nasdaq listing rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® pl...
September 29, 2023, 8:51 pm
Dyadic to present at industry and investor events in october
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnolo...
September 29, 2023, 8:30 am
Poolbeg pharma closes chapter on patent challenge
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical group, has announced the cancellation of the European Patent Office (...
September 29, 2023, 2:47 am
immunome: the morphimmune merger and the pipeline
IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new ...
September 28, 2023, 3:11 pm
Kineta announces participation at october investor conferences
SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
September 28, 2023, 9:30 am
immunovant announces pricing of $450 million common stock financing
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — immunovant, Inc. (Nasdaq: IMVT), a clinical-stage ...
September 28, 2023, 3:41 am
23andme announces poster presentations on 23me-00610, an investigational antibody targeting cd200r1, at the society for immunotherapy of cancer’s (sitc) 2023 annual meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid...
September 27, 2023, 8:05 pm
Moonlake immunotherapeutics is now thoroughly de-risked
MoonLake immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 tr...
September 27, 2023, 8:00 pm
Cellectis to present pre-clinical data on multi-armored allogeneic muc1-car t-cells targeting triple-negative breast cancer at the society for immunotherapy of cancer (sitc) 38th annual meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com...
September 27, 2023, 4:30 pm
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de...
September 27, 2023, 4:01 pm
Candel therapeutics announces three abstracts accepted for poster presentations at sitc 2023 annual meeting
One clinical poster detailing initial overall survival and immunological biomarker data from the ongoin...
September 27, 2023, 1:40 pm
Coherus announces three presentations at the 38th annual meeting of the society for immunotherapy of cancer (sitc)
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three...
September 27, 2023, 1:10 pm